

Examiner-Initiated Interview Summary

Application No.

09/916,017

Applicant(s)

DEBENEDETTI ET AL.

Examiner

J. Eric Angell

Art Unit

1635

All Participants:

(1) J. Eric Angell.

(2) Stephen Albiny-Jenei.

Status of Application: _____

(3) _____

(4) _____

Date of Interview: _____

Time: _____

Type of Interview:

☒ Telephonic

☐ Video Conference

☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No

If Yes, provide a brief description:

Part I.

Rejection(s) discussed:

112, 1st paragraph rejection based on the deltaG value related to the stability of the 5'UTR sequences encompassed by the claims.

Claims discussed:

All rejected claims, as they depend on claim 10 or 21

Prior art documents discussed:

Shimogori

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

Part III.

- ☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: Applicants were informed of the problems identified by the Examiner with respect to the the deltaG value related to the stability of the 5'UTR sequences encompassed by the claims. Applicants agreed to submit additional information and possibly claim amendments to clarify the stability of the 5'UTRs encompassed by the claims..

(FILE 'HOME' ENTERED AT 17:06:41 ON 16 APR 2002)

FILE 'MEDLINE, BIOSIS, CANCERLIT, CAPLUS, SCISEARCH, EMBASE' ENTERED AT
17:06:54 ON 16 APR 2002

L1 0 S DEBENEDETTI/AU AND DEFATTA/AU
L2 99 S (DEBENEDETTI A OR DEBENEDETTI, A)/AU
L3 82 DUP REM L2 (17 DUPLICATES REMOVED)
L4 3 S L3 AND (DEFATTA RJ OR DEFATTA, RJ OR DEFATTA R.J.)/AU
L5 3 DUP REM L4 (0 DUPLICATES REMOVED)
L6 3 S DEBENEDETTI?/AU AND DEFATTA?/AU
L7 0 S DEFATTA RJ/AU
L8 24 S DEFATTA?/AU
L9 8 DUP REM L8 (16 DUPLICATES REMOVED)
L10 32 S L3 AND EIF?
L11 32 DUP REM L10 (0 DUPLICATES REMOVED)
L12 0 S (SUICIDE VECTORS) AND (GENE THERAPY) AND (THYMADINE KINASE) A
L13 0 S (GENE THERAPY) AND (THYMADINE KINASE) AND REVIEW
L14 382 S (GENE THERAPY) AND (THYMIDINE KINASE) AND REVIEW
L15 23 S (GENE THERAPY) AND (THYMIDINE KINASE)/TI AND REVIEW
L16 15 DUP REM L15 (8 DUPLICATES REMOVED)
L17 0 S (SPRINGER CJ)/AU AND (GENE THERAPY)/TI
L18 68 S ((SPRINGER CJ)OR (SPRINGER, CJ) OR (SPRINGER?))/AU AND (GENE
L19 23 DUP REM L18 (45 DUPLICATES REMOVED)
L20 1052 S EIF4?/TI
L21 573 S (EIF4E OR EIF4-E)/TI
L22 1 S (EIF4E OR EIF4-E)/TI AND (GENE THERAPY)
L23 0 S (EIF4E OR EIF4-E)/TI AND SUICIDE
L24 0 S EIF4?/TI AND SUICIDE
L25 6 S EIF4?/TI AND (GENE THERAPY)
L26 2 DUP REM L25 (4 DUPLICATES REMOVED)
L27 9 S EIF4? AND (GENE THERAPY)
L28 5 DUP REM L27 (4 DUPLICATES REMOVED)